- Home
- BLIV vs SCLX Comparison
BLIV vs SCLX Comparison
Compare BLIV & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIV
- SCLX
- Stock Information
- Founded
- BLIV 2014
- SCLX 2011
- Country
- BLIV Singapore
- SCLX United States
- Employees
- BLIV N/A
- SCLX N/A
- Industry
- BLIV
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- BLIV
- SCLX Health Care
- Exchange
- BLIV NYSE
- SCLX Nasdaq
- Market Cap
- BLIV 39.8M
- SCLX 33.9M
- IPO Year
- BLIV 2025
- SCLX N/A
- Fundamental
- Price
- BLIV $3.79
- SCLX $4.73
- Analyst Decision
- BLIV
- SCLX Strong Buy
- Analyst Count
- BLIV 0
- SCLX 3
- Target Price
- BLIV N/A
- SCLX $367.50
- AVG Volume (30 Days)
- BLIV 68.2K
- SCLX 135.7K
- Earning Date
- BLIV 01-01-0001
- SCLX 08-12-2025
- Dividend Yield
- BLIV N/A
- SCLX N/A
- EPS Growth
- BLIV N/A
- SCLX N/A
- EPS
- BLIV N/A
- SCLX N/A
- Revenue
- BLIV $1,355,200.00
- SCLX $50,710,000.00
- Revenue This Year
- BLIV N/A
- SCLX $107.00
- Revenue Next Year
- BLIV N/A
- SCLX $82.52
- P/E Ratio
- BLIV N/A
- SCLX N/A
- Revenue Growth
- BLIV N/A
- SCLX 7.79
- 52 Week Low
- BLIV $2.69
- SCLX $3.60
- 52 Week High
- BLIV $6.40
- SCLX $78.05
- Technical
- Relative Strength Index (RSI)
- BLIV N/A
- SCLX 42.52
- Support Level
- BLIV N/A
- SCLX $4.56
- Resistance Level
- BLIV N/A
- SCLX $4.90
- Average True Range (ATR)
- BLIV 0.00
- SCLX 0.58
- MACD
- BLIV 0.00
- SCLX -0.10
- Stochastic Oscillator
- BLIV 0.00
- SCLX 4.73
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.